Discover What's Next in Biopharma M&A and Licensing

The 2025 Dealmakers' Intentions Survey is here! Now in its 15th year, this report offers a forward-looking view of dealmaking trends, investment hotspots and key factors shaping the biopharmaceutical landscape in the year ahead.

Inside, you'll find:

• A retrospective on 2024 deal activity—and why it was the slowest in a decade
• Insights into 2025 dealmaker sentiment: Will M&A and financing recover?
• The top therapy areas and technologies capturing investor interest
• A deep dive into oncology, genetic medicine and AI-driven deal opportunities
• Expert perspectives on deal hurdles, including valuation gaps and financing challenges

Whether you're a buyer, seller or investor, this report provides the data and strategic insights you need to navigate 2025's evolving deal landscape.

 
Download your copy now to stay ahead in biopharma dealmaking.